CLAIMS

1. Use of a substance including an RNA pathogen mimic with a delivery agent comprising polyethylenimine (PEI), in the manufacture of a medicament for the treatment of a tumor of a patient, wherein the administration pattern of the medicament comprises administration of a therapeutically effective amount of the substance to the patient, in one or more sessions, followed by treatment of the tumor with intra-tumoral alpha-emitter radiotherapy less than two weeks after administration of the substance, and at least 12 hours after administration of a last dose of the substance.

2. The use of claim 1, wherein the substance comprises polyIC with polyethylenimine (PEI).

3. The use of claim 1, wherein the substance comprises poly-ICLC.

4. The use of claim 1, wherein the substance comprises an oncolytic virus.

5. The use of claim 1, wherein the substance comprises BO-112.

6. The use of any one of claims 1-5, wherein the administration pattern of the medicament further comprises administration of a supportive treatment drug for checkpoint inhibition.

7. The use of claim 6, wherein the supportive treatment drug comprises a checkpoint blockade.

8. The use of any one of claims 1-7, wherein the intra-tumoral alpha-emitter radiotherapy is provided by a source carrying radium atoms.

9. The use of any one of claims 1-8, wherein the intra-tumoral alpha-emitter radiotherapy is provided by a source carrying alpha-emitting atoms mounted on the source in a manner which allows controllable release of the alpha-emitting atoms or their daughter radionuclides from the source.